Basel remains the key biotech area in Switzerland. Biotech companies in Basel Area (Basel-Stadt and Basel-Landschaft) benefited from the investment of 328 million Swiss francs, out of the total 739 million Swiss francs from investors, in 2024. The figure (44%) eclipses the investment into the sector in other regions of the country.
Biotech startups Alentis Therapeutics, Bright Peak Therapeutics, based in the Switzerland Innovation Park Basel Area, heavily benefited from the investment. Other biotech companies in Basel Area such as Noema Pharma, NXI Therapeutics, Allegria Therapeutics, FimmCyte, Myria Biosciences, Inofea, and KetoSwiss received significant fundings.
The biotech sector in the Basel Area is aided by the presence of 14 internationally recognized research institutes, and six of the top 20 universities in biosciences. Proximity to France and Germany is another factor.
The Roche Innovation Center Basel, is investing in research areas such as oncology, ophthalmology, rare diseases, neuroscience, and infectious diseases, while Novartis has many dedicated sites for research and development.
In addition to the two Swiss pharma giants, Roche and Novartis, Basel is also home to top global giants like Lonza, BeiGene, Regeneron Pharmaceuticals, Moderna, and Swedish Orphan Biovitrum.
